Další formáty:
BibTeX
LaTeX
RIS
@article{1408003,
author = {Pleva, L. and Kukla, P. and Zapletalova, J. and Hlinomaz, Ota},
article_location = {London},
article_number = {6},
doi = {http://dx.doi.org/10.1186/s12872-017-0602-6},
keywords = {In-stent restenosis; Paclitaxel-elution balloon; Drug-eluting stent},
language = {eng},
issn = {1471-2261},
journal = {BMC Cardiovascular Disorders},
title = {Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis},
volume = {17},
year = {2017}
}
TY - JOUR
ID - 1408003
AU - Pleva, L. - Kukla, P. - Zapletalova, J. - Hlinomaz, Ota
PY - 2017
TI - Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis
JF - BMC Cardiovascular Disorders
VL - 17
IS - 6
SP - 1-9
EP - 1-9
PB - Biomed Central Ltd
SN - 14712261
KW - In-stent restenosis
KW - Paclitaxel-elution balloon
KW - Drug-eluting stent
N2 - Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR). Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis and 12-month major adverse cardiac events (MACE). Results: Compared to iopromide-coated PEB, seal-wing PEB was associated with significantly higher 12-month LLL (0.30 vs. 0.02 mm; p < 0.0001), repeated binary restenosis (28.12% vs. 8.7%; p = 0.012), 12-month MACE (26.98% vs. 10.29%; p = 0.003), and target vessel revascularization (TVR; 20.63% vs. 7.35%; p = 0.009). Compared to EES, no significant differences were found in the 12-month LLL (0.30 vs. 0.19 mm; p = 1.000), repeated binary restenosis (28.12% vs. 19.12%; p = 0.666), 12-month MACE (26.98% vs. 19.12%; p = 0.102) or TVR (20.63% vs. 16.18%; p = 0.360). Conclusion: BMS-ISR treatment using seal-wing PEB led to significantly higher 12-month LLL, repeated binary restenosis, MACE, and TVR compared to iopromide-coated PEB. However, no significant differences were found in comparison with EES.
ER -
PLEVA, L., P. KUKLA, J. ZAPLETALOVA a Ota HLINOMAZ. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. \textit{BMC Cardiovascular Disorders}. London: Biomed Central Ltd, roč.~17, č.~6, s.~1-9. ISSN~1471-2261. doi:10.1186/s12872-017-0602-6. 2017.
|
